An Israeli study appears to support findings from Pfizer and BioNTech that three doses of their vaccine, including a booster as well as an initial two-shot regimen, provide strong protection against the omicron variant, Reuters reported.
The blood samples of 20 people who received a third shot of the Pfizer vaccine one month ago and those of 20 people who received a second dose of the vaccine between five and six months ago were analyzed by researchers from the Israeli Ministry of Health’s Central Virology Laboratory and Sheba Medical Center, according to the news outlet.
The director of the Infectious Diseases Unit at Sheba Medical Center, Gili Regev-Yochay, said that while there was no neutralization ability against the omicron variant in those who had received their second shot five or six months ago, “the good news is that with the booster dose it increases about a hundred fold,” Reuters reported.
“There is a significant protection of the booster dose,” she added.
However, she also said that the protection offered against omicron “is lower than the neutralization ability against the Delta, about four times lower.”
Read Full Story
The Hill Rating